Cytokines have a complex role in the tumor niche, with implications extending to cancer immunotherapy. Given that immune system-based cancer therapy is among the most powerful treatments in our arsenal, it’s critical to have tools that unravel the cytokine-tumor network.

Learn of the increasing interest in IL-10, IL-4, and TGF-β cytokines and how they create an immunosuppresive environment in the tumor niche¹. Advance your cancer research with our recombinant proteins.

Tumor cells can express high levels of immune checkpoint receptors, which can lead to suppression of anti-tumor T cell and inflammatory responses. Research looks to unblock this suppression or activate a productive immune response. Decipher the complexity of the tumor niche with our immune checkpoint biotinylated recombinant proteins, which are essential for studying cancer biology. In addition, you can learn more about recombinant cytokines, such as IFN-α and IL-2, that augment anti-tumor inflammatory responses as part of immunotherapies. 

We provide researchers with tools to investigate the interaction between SARS-CoV-2 virus and its host cell. Tools, such as our LEAF™ Purified anti-human ACE2 antibody (clone Poly5036) that inhibits the binding of spike protein to ACE2, can lead to strategies for developing drugs that block SARS-CoV-2 infection or treat COVID-19. 

View our full suite of tools for dismantling SARS-CoV-2.

Biotinylated recombinant SARS-CoV-2 Spike protein S1 (black circles) (Cat. No. 793806) binds to immobilized recombinant human ACE2-Fc chimera (carrier-free) (Cat. No. 793206). LEAF purified anti-human ACE2 antibody (Poly5036) (purple squares) inhibits the binding in a dose-dependent manner whereas the LEAF purified goat IgG isotype ctrl antibody (gray triangles) does not have the effect. This antibody blocks the binding of 0.5 µg/mL biotinylated recombinant SARS-CoV-2 Spike protein S1 (Cat. No. 793806) to 1 µg/mL immobilized recombinant human ACE2-Fc chimera (carrier-free). ND50 = 1 - 6 µg/mL.